BRCA1/2 sequence variants of uncertain significance: A primer for providers to assist in discussions and in medical management

Noralane Morey Lindor, David E. Goldgar, Sean V. Tavtigian, Sharon E. Plon, Fergus J Couch

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Introduction.DNAvariants of uncertain significance (VUS) are commonoutcomes of clinical genetic testing for susceptibility to cancer.Astatistically rigorousmodelthat providesapathogenicity score foreachvariant hasbeendevelopedto aid in the clinical management of patients undergoing genetic testing. Methods. The information in this article is derived from multiple publications on VUS in BRCA genes, distilled for communicating with clinicians who may encounter VUS in their practice. Results. The posterior probability scores for BRCA1 or BRCA2 VUS, calculated from a multifactorial likelihood model, are explained, and links for looking up specific VUS are provided. The International Agency on Cancer Research (IARC) of the World Health Organization has proposed a simple five-tier system for clinical management that is not widely known to clinicians. Classes 1 and 2 in this system are managed as neutral variants, classes 4 and 5 are managed as pathogenic variants, and class 3 variants still have insufficient evidence to move to either end of this scale and, thus, cannot be used in medical management. Conclusions. Development of models that integrate multiple independent lines of evidence has allowed classification of a growing number of VUS in the BRCA1 and BRCA2 genes. The pathogenicity score that is generated by this model maps to the IARC system for clinical management, which will assist clinicians in the medical management of those patients who obtain a VUS result upon testing.

Original languageEnglish (US)
Pages (from-to)518-524
Number of pages7
JournalOncologist
Volume18
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

International Agencies
Genetic Testing
BRCA2 Gene
BRCA1 Gene
Neoplasms
Genetic Predisposition to Disease
Research
Virulence
Publications
Genes

Keywords

  • BRCA1
  • BRCA2
  • Counseling
  • Likelihood
  • Management
  • Multifactorial

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

BRCA1/2 sequence variants of uncertain significance : A primer for providers to assist in discussions and in medical management. / Lindor, Noralane Morey; Goldgar, David E.; Tavtigian, Sean V.; Plon, Sharon E.; Couch, Fergus J.

In: Oncologist, Vol. 18, No. 5, 05.2013, p. 518-524.

Research output: Contribution to journalArticle

@article{4caeb969ac654bbda25e141e0c411c4c,
title = "BRCA1/2 sequence variants of uncertain significance: A primer for providers to assist in discussions and in medical management",
abstract = "Introduction.DNAvariants of uncertain significance (VUS) are commonoutcomes of clinical genetic testing for susceptibility to cancer.Astatistically rigorousmodelthat providesapathogenicity score foreachvariant hasbeendevelopedto aid in the clinical management of patients undergoing genetic testing. Methods. The information in this article is derived from multiple publications on VUS in BRCA genes, distilled for communicating with clinicians who may encounter VUS in their practice. Results. The posterior probability scores for BRCA1 or BRCA2 VUS, calculated from a multifactorial likelihood model, are explained, and links for looking up specific VUS are provided. The International Agency on Cancer Research (IARC) of the World Health Organization has proposed a simple five-tier system for clinical management that is not widely known to clinicians. Classes 1 and 2 in this system are managed as neutral variants, classes 4 and 5 are managed as pathogenic variants, and class 3 variants still have insufficient evidence to move to either end of this scale and, thus, cannot be used in medical management. Conclusions. Development of models that integrate multiple independent lines of evidence has allowed classification of a growing number of VUS in the BRCA1 and BRCA2 genes. The pathogenicity score that is generated by this model maps to the IARC system for clinical management, which will assist clinicians in the medical management of those patients who obtain a VUS result upon testing.",
keywords = "BRCA1, BRCA2, Counseling, Likelihood, Management, Multifactorial",
author = "Lindor, {Noralane Morey} and Goldgar, {David E.} and Tavtigian, {Sean V.} and Plon, {Sharon E.} and Couch, {Fergus J}",
year = "2013",
month = "5",
doi = "10.1634/theoncologist.2012-0452",
language = "English (US)",
volume = "18",
pages = "518--524",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - BRCA1/2 sequence variants of uncertain significance

T2 - A primer for providers to assist in discussions and in medical management

AU - Lindor, Noralane Morey

AU - Goldgar, David E.

AU - Tavtigian, Sean V.

AU - Plon, Sharon E.

AU - Couch, Fergus J

PY - 2013/5

Y1 - 2013/5

N2 - Introduction.DNAvariants of uncertain significance (VUS) are commonoutcomes of clinical genetic testing for susceptibility to cancer.Astatistically rigorousmodelthat providesapathogenicity score foreachvariant hasbeendevelopedto aid in the clinical management of patients undergoing genetic testing. Methods. The information in this article is derived from multiple publications on VUS in BRCA genes, distilled for communicating with clinicians who may encounter VUS in their practice. Results. The posterior probability scores for BRCA1 or BRCA2 VUS, calculated from a multifactorial likelihood model, are explained, and links for looking up specific VUS are provided. The International Agency on Cancer Research (IARC) of the World Health Organization has proposed a simple five-tier system for clinical management that is not widely known to clinicians. Classes 1 and 2 in this system are managed as neutral variants, classes 4 and 5 are managed as pathogenic variants, and class 3 variants still have insufficient evidence to move to either end of this scale and, thus, cannot be used in medical management. Conclusions. Development of models that integrate multiple independent lines of evidence has allowed classification of a growing number of VUS in the BRCA1 and BRCA2 genes. The pathogenicity score that is generated by this model maps to the IARC system for clinical management, which will assist clinicians in the medical management of those patients who obtain a VUS result upon testing.

AB - Introduction.DNAvariants of uncertain significance (VUS) are commonoutcomes of clinical genetic testing for susceptibility to cancer.Astatistically rigorousmodelthat providesapathogenicity score foreachvariant hasbeendevelopedto aid in the clinical management of patients undergoing genetic testing. Methods. The information in this article is derived from multiple publications on VUS in BRCA genes, distilled for communicating with clinicians who may encounter VUS in their practice. Results. The posterior probability scores for BRCA1 or BRCA2 VUS, calculated from a multifactorial likelihood model, are explained, and links for looking up specific VUS are provided. The International Agency on Cancer Research (IARC) of the World Health Organization has proposed a simple five-tier system for clinical management that is not widely known to clinicians. Classes 1 and 2 in this system are managed as neutral variants, classes 4 and 5 are managed as pathogenic variants, and class 3 variants still have insufficient evidence to move to either end of this scale and, thus, cannot be used in medical management. Conclusions. Development of models that integrate multiple independent lines of evidence has allowed classification of a growing number of VUS in the BRCA1 and BRCA2 genes. The pathogenicity score that is generated by this model maps to the IARC system for clinical management, which will assist clinicians in the medical management of those patients who obtain a VUS result upon testing.

KW - BRCA1

KW - BRCA2

KW - Counseling

KW - Likelihood

KW - Management

KW - Multifactorial

UR - http://www.scopus.com/inward/record.url?scp=84878212439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878212439&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2012-0452

DO - 10.1634/theoncologist.2012-0452

M3 - Article

C2 - 23615697

AN - SCOPUS:84878212439

VL - 18

SP - 518

EP - 524

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -